A recurring theme at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t a single dataset, biomarker, or therapy. | ASCO 2026 highlighted a new reality: precision oncology’s future depends not only on discovery, but on translating innovation into patient care.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann | Each…
There were 487 exhibitor booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting, held in Chicago’s…
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various…
